-
Nov 18, 2024 | 
jamanetwork.com | Robert W. Yeh |Jennifer Ho |Dhruv S. Kazi
Semaglutide Eligibility Across All Current Indications for US Adults
Rapidly increasing uptake of semaglutide made it the top-selling drug in the US in 2023, with net sales of $13.8 billion.1,2 Quantifying the number of US adults eligible for semaglutide may guide future policies for this high-cost therapy and clarify potential implications for pharmaceutical spending.
-
Jul 31, 2024 | 
jamanetwork.com | Andrew Wilcock |Robert W. Yeh |Lee H. Schwamm |Ateev Mehrotra
Key PointsQuestion
What underlies the sustained reduction in acute myocardial infarction (AMI) hospital encounters that began during the COVID-19 pandemic?
-
Jun 13, 2024 | 
jamanetwork.com | Allison Kratka |Rita F. Redberg |Robert W. Yeh |Richard A Shlofmitz
Paclitaxel-Coated Balloon vs Uncoated Balloon for Coronary In-Stent Restenosis Robert W. Yeh, MD, MSc; Richard Shlofmitz, MD; Jeffrey Moses, MD; William Bachinsky, MD; Suhail Dohad, MD; Steven Rudick, MD; Robert Stoler, MD; Brian K. Jefferson, MD; William Nicholson, MD; John Altman, MD; Cinthia Bateman, MD; Amar Krishnaswamy, MD; J. Aaron Grantham, MD; Frank J. Zidar, MD; Steven P. Marso, MD; Jennifer A. Tremmel, MD, MS; Cindy Grines, MD; Mustafa I. Ahmed, MD; Azeem Latib, MD; Behnam Tehrani, MD; J.
-
Jun 13, 2024 | 
jamanetwork.com | Robert W. Yeh |Ajay Kirtane |Richard A Shlofmitz |Jeffrey W. Moses
Coronary In-Stent Restenosis Treated With Paclitaxel-Coated Balloon vs Uncoated Balloon—Reply Paclitaxel-Coated Balloon vs Uncoated Balloon for Coronary In-Stent Restenosis Robert W. Yeh, MD, MSc; Richard Shlofmitz, MD; Jeffrey Moses, MD; William Bachinsky, MD; Suhail Dohad, MD; Steven Rudick, MD; Robert Stoler, MD; Brian K. Jefferson, MD; William Nicholson, MD; John Altman, MD; Cinthia Bateman, MD; Amar Krishnaswamy, MD; J. Aaron Grantham, MD; Frank J.
-
Apr 17, 2024 | 
medscape.com | Robert Harrington |Robert W. Yeh
This transcript has been edited for clarity. Robert A. Harrington, MD: Hi. This is Bob Harrington from Weill Cornell Medicine on Medscape Cardiology | theheart.org. Over the years, we've talked often on this show about randomized clinical trials. We talk about some of the latest research coming out of observational analyses, outcomes-based research, and we've had discussions about which one is a better form of evidence or a stronger form of evidence. Is it the randomized clinical trial?
-
Apr 12, 2024 | 
jamanetwork.com | Timothy Anderson |Edward R. Marcantonio |Robert W. Yeh |Jeffrey Souza
Key PointsQuestion
Has Medicare’s implementation of payments for transitional care management (TCM) services been associated with an increase in timely primary care follow-up after medical facility discharge?
-
Mar 12, 2024 | 
healio.com | Erik Swain |Richard Smith |Dmitriy N. Feldman |Robert W. Yeh
Dmitriy N. Feldman, MDFor patients with in-stent restenosis, paclitaxel-coated balloons will be an important and effective new therapy, superior to uncoated balloon angioplasty. Importantly, for high-risk patients with multiple prior stents at the site of the restenosis, where additional stenting would reduce lumen area and not be ideal, paclitaxel-coated technology will become first-line therapy for in-stent restenosis.
-
Mar 9, 2024 | 
jamanetwork.com | Robert W. Yeh |Richard A Shlofmitz |Jeffrey W. Moses |William Bachinsky
Key PointsQuestion
Is treatment with a coronary paclitaxel-coated balloon superior to an uncoated balloon for 1-year target lesion failure in patients undergoing percutaneous coronary intervention for in-stent restenosis? Findings
In a multicenter randomized trial of 600 patients designed to support US regulatory approval, target lesion failure was significantly lower in the paclitaxel-coated balloon group (17.9%) compared with the uncoated balloon group (28.6%) (P = .003).
-
Mar 1, 2024 | 
healio.com | Erik Swain |Robert W. Yeh
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways:The FDA approved a paclitaxel-coated balloon as an alternative treatment of coronary in-stent restenosis. The approval was based on the positive results of the AGENT IDE trial.
-
Nov 25, 2023 | 
nejm.org | Daniel Kramer |Robert W. Yeh
November 30, 2023N Engl J Med 2023; 389:2021-2024 DOI: 10.1056/NEJMp2308736 DownloadA new pathway proposed by the Centers for Medicare and Medicaid Services aims to expedite access to breakthrough devices while preserving Medicare’s independent role in evidence generation. Funding and Disclosures Disclosure forms provided by the authors are available at NEJM.org. This article was published on November 25, 2023, at NEJM.org.
